pinch oce dollop nextgen
saw biggest book histori compani
rais fy revenu ebitda ep guidanc due o/
 less-than expect pass-through better expect
growth ebp emerg biopharma book
nextgen award custom
ad new client year due chang go-to-
continu hw growth margin
isi thesi updat ad plenti sugar spice
everyth nice got across board beat
rais strong book increment construct commentari
manag continu back belief growth acceler
continu buyback share gain stori final start play
continu nextgen momentum oce inflect
commerci key proof point given scarciti entiti
compound surpris notabl multipl
re-rat furthermor look continu institut add
must core hold la that pretti
tailwind palat valuat given superior growth profil
reiter outperform rate rais pt expect share
continu steadi march higher hold broaden long
commun oddli absent top list
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
rais revenu mm vs mm prior
 mm due oper mm due pass-through mm more-than-expect contribut
 rememb manag guid pass-through sale bn mm commerci remaind
solut call
 bn remain author
fy guidanc inclus
 lower fx impact manag expect hw lower contribut
look bp omx
 largest book valu quarter ever w/ book growth ebp custom
 mm new busi associ nextgen bring total nextgen book bn sinc merger
 book-to-bil w/ pass-through
 adjust backlog fx etc would
 book-to-bil ex pass-through
 use award basi comp peer would well north
technolog analyt solut ta use commerci solut grew organ
 applic grow dd data piec tas/commerci
 anoth signific win real-world top pharma client
 award top client clinic tech applic
 new award top pharma client standard oce platform global top roll oce top therapeut
market specialti space across countri
contract sale medic solut csm use organ
bn nextgen award sinc merger mm
 book ebp custom
 see win rate nextgen project vs tradit trial
oce competitor hold market share take share multi-year event
 adopt hw margin implement take depend contract signific invest need
made
see hefti uptick work pass-through revenu lower margin manag isnt call complet
switch market vs strateg partnership
get price nextgen work industri remain incred competit switch cost remain
nextgen book come ebp custom repres biggest growth area industri
move away target due valuat
valuat methodolog valuat methodolog base mix discount cash flow analysi rel valuat
risk disrupt revenu growth inabl replac unforeseen cancel new busi moder
biotech demand due capit market volatil dri invest paus rfp activ follow larg round
pharma industri consolid
laboratori corp america hold
articl articl
time dissemin juli et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
